# Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

> **NCT04532229** · PHASE3 · UNKNOWN · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** Nimotuzumab+CRT(concurrent IMRT and TMZ)

## Key facts

- **NCT ID:** NCT04532229
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-03
- **Primary completion:** 2023-10-08
- **Final completion:** 2023-12-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04532229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04532229, "Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04532229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*